<DOC>
	<DOCNO>NCT00942136</DOCNO>
	<brief_summary>GSK1349572 integrase inhibitor currently evaluate treatment HIV infection . The primary objective study determine whether addition proton pump inhibitor , omeprazole , GSK1349572 impact blood level GSK1349572 . It also evaluate high fat meal impact blood level GSK1349572 . In addition , safety , tolerability , pharmacokinetics single supratherapeutic ( high ) dose GSK1349572 evaluate .</brief_summary>
	<brief_title>GSK1349572 Proton Pump Inhibitor Drug Interaction Supratherapeutic Dose Study</brief_title>
	<detailed_description>Official Study Title : A randomized , double-blind study evaluate safety , tolerability , pharmacokinetics supratherapeutic dose GSK1349572 250 mg randomize , open-label study evaluate effect omeprazole 40 mg daily high fat meal pharmacokinetics GSK1349572 50 mg healthy adult subject ( ING112941 )</detailed_description>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Male female 18 65 year age , inclusive . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory ] , Childbearing potential agrees use one contraception method list protocol appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 3 day last dose study drug . Body weight ≥ 50 kg men ≥ 45 kg woman BMI within range 18.531.0 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . AST , ALT , alkaline phosphatase bilirubin ≤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . A single repeat allow eligibility determination . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody . A positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . History regular alcohol consumption within 6 month study define : average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 ml ) beer , 5 ounce ( 150 ml ) wine 1.5 ounce ( 45 ml ) 80 proof distil spirit . History regular use tobacco nicotinecontaining product within 3 month prior screen . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Consumption red wine , seville orange , grapefruit grapefruit juice 7 day prior first dose study medication . History sensitivity study medication , component thereof include sulfacontaining drug , history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive serum urine human hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . If heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol . History significant renal hepatic disease . History/evidence clinically significant pulmonary disease . History/evidence symptomatic arrhythmia , angina/ischemia , coronary artery bypass grafting ( CABG ) surgery percutaneous transluminal coronary angioplasty ( PCTA ) clinically significant cardiac disease . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy , inflammatory bowel disease , pancreatitis exclude . Subjects gastroesophageal reflux disease require use proton pump inhibitor H2blockers . History upper gastrointestinal bleeding . Active peptic ulcer disease . Subjects hemoglobin &lt; 12 g/dL . A single repeat allow eligibility determination . The subject 's systolic blood pressure outside range 90140mmHg , diastolic blood pressure outside range 4590mmHg heart rate outside range 50100bpm female subject 45100 bpm male subject . A single repeat allow determine subject eligibility . Exclusion criterion screen ECG ( single repeat allow eligibility determination ) outside protocol limit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>HIV</keyword>
	<keyword>GSK1349572</keyword>
	<keyword>omeprazole</keyword>
	<keyword>Prilosec</keyword>
	<keyword>supratherapeutic dose</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>drug interaction</keyword>
	<keyword>HIV Infections</keyword>
</DOC>